EUROPEAN RENAL ASSOCIATION - EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION
Services
How to use the platform
Build a poster
MANAGE ORDERS
FAQs
Contact
HOMEPAGE
Virtual Poster Gallery
PrintingOnline for Collection on-site
Accredited Training
DOI - Digital Object Identifier
What is PosterSessionOnline?
How to send your poster
How to visit the Virtual Poster Gallery
How to build a poster
How to reduce a poster to less than 2 Mb
PosterSessionOnline Image Editor
How to build a poster with our templates
How to work with a template
Templates and instructions
Discussion forum -
49th ERA-EDTA Congress
Topic -
Acid-base / Electrolytes
If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER.
Poster:
177
Visits:
1275
Title:
RDX5791, a non-systemic NHE3 inhibitor for the treatment of fluid and sodium overload, shifts sodium excretion from urine to feces in healthy subjects
Authors:
Dominique Charmot ,
Centre:
Ardelyx Inc.
You must be registered to reply or comment.
RDX5791, A NON-SYSTEMIC NHE3 INHIBITOR FOR THE TREATMENT OF FLUID AND SODIUM OVERLOAD, SHIFTS SODIUM EXCRETION FROM URINE TO FECES IN HEALTHY SUBJECTS
Dominique Charmot
Thread initiator
Subspeciality
Reg:
5/7/2012 12:55:00 AM
Comment# 1
Management of fluid overload in CKD / ESRD patients
Comment added on 5/7/2012 12:55:00 AM
You must be registered to reply or comment.
Most viewed poster for this congress
Poster:
424
Visits:
2636
Title:
Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Glomerulonephritides: an Immunohystochemical expression analysis
Authors:
Giuseppe Coppolino ,
Centre:
Chair of Nephrology, University Magna Graecia of Catanzaro, Catanzaro, Italy
Poster most viewed in this topic
Poster:
177
Visits:
1275
Title:
RDX5791, a non-systemic NHE3 inhibitor for the treatment of fluid and sodium overload, shifts sodium excretion from urine to feces in healthy subjects
Authors:
Dominique Charmot ,
Centre:
Ardelyx Inc.
View Poster Gallery
Back to congress home
Other Congresses
About us
|
Terms and Conditions
|
Special Access